Cabozantinib belongs to which category of targeted drugs and what is its mechanism?

Cabozantinib (Cabozantinib) is an oral multi-target tyrosine kinase inhibitor (TKI), which is widely used in the treatment of various solid tumors such as renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Its mechanism of action is complex and multi-targeted. The following introduces the drug classification and mechanism of action of cabozantinib from different perspectives:

Cabozantinib is a multi-target tyrosine kinase inhibitor. It mainly targets VEGFR (vascular endothelial growth factor receptor), MET (hepatocyte growth factor receptor) and AXL AXL, which are closely related to tumor growth and metastasis. This multi-target characteristic enables cabozantinib not only to have an anti-tumor proliferation effect, but also to effectively inhibit the formation of tumor-related blood vessels, reduce the blood and oxygen supply to the tumor, thereby blocking further expansion of the tumor.

InhibitingMET signaling pathway is one of its core advantages. MET is a tyrosine kinase receptor that is overexpressed or abnormally activated in a variety of tumors and is involved in the growth, invasion and metastasis of tumor cells. Cabozantinib can block the migration and invasion abilities of tumor cells by inhibiting the MET pathway, and shows particularly significant efficacy in tumors with abnormally MET activity.

Anti-angiogenic anti-cancer mechanisms enhance efficacy. Cabozantinib inhibits VEGFR1, VEGFR2 and VEGFR3, effectively blocking the formation of new blood vessels in tumors. This is especially important for cancers that are highly dependent on blood vessels (such as kidney cancer, liver cancer). Cutting off the nutrient supply by "starving" the tumor, combined with its anti-proliferative effect, makes the treatment more comprehensive.

AXLTarget inhibition helps overcome drug resistance. AXL is a kinase related to tumor drug resistance and immune evasion. By simultaneously inhibiting AXL, cabozantinib can intervene in the resistance mechanism of tumors after receiving anti-VEGF or other targeted therapies and improve the overall therapeutic effect. Therefore, cabozantinib still has good application value after multiple lines of treatment, especially for patients who are resistant to or relapsed from previous treatments.

Reference materials:https://www.drugs.com/